Free Trial
→ Shots officially fired… (From Brownstone Research) (Ad)tc pixel
Justin Zelin

Justin Zelin Analyst Performance

Director, Biotechnology Equity Research Analyst at BTIG Research

Justin Zelin is a stock analyst at BTIG Research in the medical sector, covering 7 publicly traded companies. Over the past year, Justin Zelin has issued 7 stock ratings, including and buy recommendations. While full access to Justin Zelin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Zelin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 4 Years
Buy Recommendations
100.00% 13 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%13 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
TSE
14.3% of companies on TSE
1 company

Justin Zelin, an analyst at BTIG Research, currently covers 7 companies listed on NASDAQ and TSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies		100.0%

Justin Zelin of BTIG Research specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies		85.7%
BIOTECHNOLOGY
1 company		14.3%

About Justin Zelin

Justin Zelin is a Director and BTIG Biotechnology Analyst, specializing in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities. Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink. Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital. He was also a member of Harvard University’s teaching staff for more than five years. Mr. Zelin earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.
Follow on LinkedIn

Justin Zelin's Ratings History at BTIG Research

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
9/22/2025Reiterated Rating$26.58$125.00Buy
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
9/22/2025Lower Price Target$2.50$7.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
9/19/2025Reiterated Rating$14.77$56.00Buy
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
9/9/2025Initiated Coverage$4.27$7.00Buy
Verastem, Inc. stock logo
VSTM
Verastem
9/9/2025Reiterated Rating$10.23$20.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
8/5/2025Boost Price Target$12.23$56.00Buy
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
7/7/2025Lower Price Target$3.04$20.00Buy
Today's Ratings
Top-Rated Stocks
More Ratings Tools